I'm happy holding.
Recommendation and valuation We initiate coverage with a BUY and place a price target of $0.092 per share, on a revenue multiple valuation, based on:
Rapid low cost conversion of pharmacies and viral patient growth.
Global pharmaceutical agreements validating the service through patient engagement campaigns.
MDR is trading at a 33% discount to listed peers based on FY18 revenue estimates
Ann: Publication of Research Note-MDR.AX, page-9
-
- There are more pages in this discussion • 6 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MDR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
30.0¢ |
Change
0.010(3.45%) |
Mkt cap ! $215.0M | |||
| Open | High | Low | Value | Volume |
| 29.0¢ | 30.0¢ | 27.5¢ | $254.8K | 889.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 39326 | 30.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 30.5¢ | 2917 | 1 |
View Market Depth
| Last trade - 16.10pm 15/11/2024 (20 minute delay) ? |
| MDR (ASX) Chart |
